We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Therapeutic Antibodies – Products

A labelled antibody and a cell.
Product News

FDA-Approved TIVDAK®: Targeting Tissue Factor in Cervical Cancer

On April 29th, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.
Quantitative Assays To Accelerate Therapeutic Antibody Development
Whitepaper

Quantitative Assays To Accelerate Therapeutic Antibody Development

This whitepaper explores the tools available to characterize antibody binding to Fc receptors, including quantitative assays to support optimization of therapeutic products.
Advancing Monoclonal Antibody Stability Studies With Mass Photometry
App Note / Case Study

Advancing Monoclonal Antibody Stability Studies With Mass Photometry

Mass photometry is an innovative biophysical analysis tool used to study the native behavior of biomolecules with minimal sample preparation.
Antibodies.
Product News

Therapeutic Potential of CD20 X CD3 Bispecific Antibodies

As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma
Antibodies attacking viruses.
Product News

ProBioGen Partners With MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease

ProBioGen, is pleased to announce the execution of services and license agreements with MAPP BIOPHARMACEUTICAL, INC. to develop a cell line for an afucosylated antibody targeting Marburg virus (MARV) infection.
A scientist in a lab.
Product News

Lonza Delivers Solid 2023 Performance With 10.9% Cer Sales Growth and 29.8% Core EBITDA Margin

Lonza has reported sales of CHF 6.7 billion, sales growth of 7.9% AER2 (10.9%1 CER), and CHF 2 billion CORE EBITDA, resulting in a margin of 29.8%.
Assays
Whitepaper

Automated Epitope Binning in a Single Assay

Binding affinity is a significant factor to consider. However, relying solely on affinity can be problematic, as the highest affinity mAbs may not exhibit optimal activity. To ensure the best lead candidates, it is crucial to consider factors like specificity, selectivity and biological relevance.
A lab working holding a glass vial that contains clear fluid and the DNA double helix.
Product News

Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer

Lonza, announced the extension of a collaboration with a major biopharmaceutical partner for the commercial-scale filling of ADCs.
Antibodies.
Product News

Lonza Further Extends Collaboration With Major Biopharmaceutical Partner for Manufacturing Antibody-Drug Conjugates

Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers.
Comprehensive Solutions for In Vitro Efficacy Evaluation
Product
Advertisement

Comprehensive Solutions for In Vitro Efficacy Evaluation

Learn more!
Advertisement